|  Help  |  About  |  Contact Us

Search our database by keyword

Examples

  • Search this entire website. Enter identifiers, names or keywords for genes, diseases, strains, ontology terms, etc. (e.g. Pax6, Parkinson, ataxia)
  • Use OR to search for either of two terms (e.g. OR mus) or quotation marks to search for phrases (e.g. "dna binding").
  • Boolean search syntax is supported: e.g. Balb* for partial matches or mus AND NOT embryo to exclude a term

Search results 301 to 331 out of 331 for Shc3

<< First    < Previous  |  Next >    Last >>
0.018s
Type Details Score
Publication
First Author: Nakamura T
Year: 1996
Journal: Oncogene
Title: N-Shc: a neural-specific adapter molecule that mediates signaling from neurotrophin/Trk to Ras/MAPK pathway.
Volume: 13
Issue: 6
Pages: 1111-21
Protein Domain
Type: Family
Description: The SH2-containing Shc adapter proteins are targets of activated tyrosine kinases and are implicated in the transmission of activation signals to the Ras/mitogen-activated protein kinase (MAPK) pathway []. Three Shc genes were originally identified in mammals that encode proteins characterised by an amino-terminal phosphotyrosine binding (PTB) domain and a carboxy-terminal Src homology 2 domain. Shc1 (ShcA) is ubiquitously expressed, whereas expression of Shc2 (ShcB) and Shc3 (ShcC) appears to be limited to neuronal cells [].Shc3 (also known as NShc from neuronal Shc) mediates neurotrophin and other neuronal signallings in the central nervous system [, ].
Publication
First Author: Ravichandran KS
Year: 2001
Journal: Oncogene
Title: Signaling via Shc family adapter proteins.
Volume: 20
Issue: 44
Pages: 6322-30
Publication
First Author: Jones N
Year: 2007
Journal: Mol Cell Biol
Title: Analysis of a Shc family adaptor protein, ShcD/Shc4, that associates with muscle-specific kinase.
Volume: 27
Issue: 13
Pages: 4759-73
Publication
First Author: Audero E
Year: 2004
Journal: J Biol Chem
Title: Adaptor ShcA protein binds tyrosine kinase Tie2 receptor and regulates migration and sprouting but not survival of endothelial cells.
Volume: 279
Issue: 13
Pages: 13224-33
Publication
First Author: Ursini-Siegel J
Year: 2012
Journal: Oncogene
Title: The ShcA SH2 domain engages a 14-3-3/PI3'K signaling complex and promotes breast cancer cell survival.
Volume: 31
Issue: 48
Pages: 5038-44
Publication
First Author: Ahn R
Year: 2013
Journal: Cancer Res
Title: The ShcA PTB domain functions as a biological sensor of phosphotyrosine signaling during breast cancer progression.
Volume: 73
Issue: 14
Pages: 4521-32
Publication
First Author: Northey JJ
Year: 2013
Journal: J Biol Chem
Title: Distinct phosphotyrosine-dependent functions of the ShcA adaptor protein are required for transforming growth factor β (TGFβ)-induced breast cancer cell migration, invasion, and metastasis.
Volume: 288
Issue: 7
Pages: 5210-22
Publication
First Author: Turco MY
Year: 2012
Journal: Stem Cells
Title: Cellular heterogeneity during embryonic stem cell differentiation to epiblast stem cells is revealed by the ShcD/RaLP adaptor protein.
Volume: 30
Issue: 11
Pages: 2423-36
Publication
First Author: Wills MK
Year: 2014
Journal: Mol Biol Cell
Title: The ShcD signaling adaptor facilitates ligand-independent phosphorylation of the EGF receptor.
Volume: 25
Issue: 6
Pages: 739-52
Publication
First Author: Zhou MM
Year: 1995
Journal: Proc Natl Acad Sci U S A
Title: Solution structure of the Shc SH2 domain complexed with a tyrosine-phosphorylated peptide from the T-cell receptor.
Volume: 92
Issue: 17
Pages: 7784-8
Protein Domain
Type: Domain
Description: The SH2-containing Shc adapter proteins are targets of activated tyrosine kinases and are implicated in the transmission of activation signals to the Ras/mitogen-activated protein kinase (MAPK) pathway []. Three Shc genes were originally identified in mammals that encode proteins characterised by an amino-terminal phosphotyrosine binding (PTB) domain and a carboxy-terminal Src homology 2 domain. Shc1 (ShcA) is ubiquitously expressed, whereas expression of Shc2 (ShcB) and Shc3 (ShcC) appears to be limited to neuronal cells [].SHC is composed of an N-terminal domain that interacts with proteins containing phosphorylated tyrosines, a (glycine/proline)-rich collagen-homology domain that contains the phosphorylated binding site, and a C-terminal SH2 domain. SH2 has been shown to interact with the tyrosine-phosphorylated receptors of EGF and PDGF and with the tyrosine-phosphorylated C chain of the T-cell receptor, providing one of the mechanisms of T-cell-mediated Ras activation []. In general SH2 domains are involved in signal transduction. They typically bind pTyr-containing ligands via two surface pockets, a pTyr and hydrophobic binding pocket, allowing proteins with SH2 domains to localize to tyrosine phosphorylated sites [, , ].
Protein Domain
Type: Family
Description: The SH2-containing Shc adapter proteins are targets of activated tyrosine kinases and are implicated in the transmission of activation signals to the Ras/mitogen-activated protein kinase (MAPK) pathway []. Three Shc genes were originally identified in mammals that encode proteins characterised by an amino-terminal phosphotyrosine binding (PTB) domain and a carboxy-terminal Src homology 2 domain. Shc1 (ShcA) is ubiquitously expressed, whereas expression of Shc2 (ShcB) and Shc3 (ShcC) appears to be limited to neuronal cells [].A fourth Shc family protein, ShcD/Shc4, is expressed in adult brain and skeletal muscle. ShcD can associate via its PTB domain with the phosphorylated muscle-specific kinase (MuSK) receptor tyrosine kinase and undergo tyrosine phosphorylation downstream of activated MuSK. Therefore, ShcD may mediate a specific aspect of signalling downstream of the MuSK receptor []. ShcD also interacts with EGFR receptor (epidermal growth factor receptor) and facilitates its ligand-independent phosphorylation []. ShcD has been shown to be a modulator in the transition of embryonic stem cell (ESC) to epiblast stem cells (EpiSCs), the initial step for ESCs to commit to differentiation [].
Protein Domain
Type: Family
Description: The SH2-containing Shc adapter proteins are targets of activated tyrosine kinases and are implicated in the transmission of activation signals to the Ras/mitogen-activated protein kinase (MAPK) pathway []. Three Shc genes were originally identified in mammals that encode proteins characterised by an amino-terminal phosphotyrosine binding (PTB) domain and a carboxy-terminal Src homology 2 domain. Shc1 (ShcA) is ubiquitously expressed, whereas expression of Shc2 (ShcB) and Shc3 (ShcC) appears to be limited to neuronal cells [].Shc1 (ShcA) adaptor transduces phosphotyrosine-dependent signals downstream of receptor tyrosine kinases (RTK) and non-RTKs, which regulates signalling pathways in breast cancer cells []. Its SH2 domain is critical for tumour survival during mammary tumorigenesis [], while its PTB domain functions as a biological sensor of phosphotyrosine signalling during breast cancer progression []. Shc1 is required for transforming growth factor beta (TGF-beta)-induced breast cancer cell migration, invasion, and metastasis []. It is also involved in signalling downstream of the angiopoietin receptor TEK/TIE2, and plays a role in the regulation of endothelial cell migration and sprouting angiogenesis [].
Protein
Organism: Mus musculus/domesticus
Length: 461  
Fragment?: false
Protein
Organism: Mus musculus/domesticus
Length: 474  
Fragment?: false
Protein
Organism: Mus musculus/domesticus
Length: 579  
Fragment?: false
Protein
Organism: Mus musculus/domesticus
Length: 626  
Fragment?: false
Protein
Organism: Mus musculus/domesticus
Length: 573  
Fragment?: false
Protein
Organism: Mus musculus/domesticus
Length: 594  
Fragment?: false
Protein
Organism: Mus musculus/domesticus
Length: 340  
Fragment?: false
Protein
Organism: Mus musculus/domesticus
Length: 262  
Fragment?: true
Protein
Organism: Mus musculus/domesticus
Length: 219  
Fragment?: false
Protein
Organism: Mus musculus/domesticus
Length: 172  
Fragment?: true
Protein
Organism: Mus musculus/domesticus
Length: 118  
Fragment?: true
Protein
Organism: Mus musculus/domesticus
Length: 280  
Fragment?: true
Publication
First Author: Grucza RA
Year: 1999
Journal: Med Res Rev
Title: SH2 domains: from structure to energetics, a dual approach to the study of structure-function relationships.
Volume: 19
Issue: 4
Pages: 273-93
Publication  
First Author: Kasembeli MM
Year: 2009
Journal: Front Biosci (Landmark Ed)
Title: SH2 domain binding to phosphopeptide ligands: potential for drug targeting.
Volume: 14
Pages: 1010-22
Publication
First Author: Filippakopoulos P
Year: 2009
Journal: Curr Opin Struct Biol
Title: SH2 domains: modulators of nonreceptor tyrosine kinase activity.
Volume: 19
Issue: 6
Pages: 643-9
Publication
First Author: Gerhard DS
Year: 2004
Journal: Genome Res
Title: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
Volume: 14
Issue: 10B
Pages: 2121-7
Publication
First Author: Huttlin EL
Year: 2010
Journal: Cell
Title: A tissue-specific atlas of mouse protein phosphorylation and expression.
Volume: 143
Issue: 7
Pages: 1174-89